Seres Therapeutics, Inc.
MCRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $13 | $1 | $4 | $0 |
| Gross Profit | -$13 | -$1 | -$4 | $0 |
| % Margin | -3,704% | – | – | – |
| R&D Expenses | $0 | $13 | $12 | $13 |
| G&A Expenses | $9 | $10 | $12 | $12 |
| SG&A Expenses | $9 | $10 | $12 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $4 |
| Operating Expenses | $9 | $24 | $24 | $29 |
| Operating Income | -$22 | -$25 | -$27 | -$29 |
| % Margin | -6,403.7% | – | – | – |
| Other Income/Exp. Net | $31 | $5 | $60 | $13 |
| Pre-Tax Income | $8 | -$20 | $33 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $8 | -$20 | $33 | -$16 |
| % Margin | 2,337.3% | – | – | – |
| EPS | 0.937 | -2.271 | 3.755 | -1.808 |
| % Growth | 141.2% | -160.5% | 307.7% | – |
| EPS Diluted | 0.935 | -2.271 | 3.75 | -1.808 |
| Weighted Avg Shares Out | 9 | 9 | 9 | 9 |
| Weighted Avg Shares Out Dil | 9 | 9 | 9 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $9 | -$19 | $34 | -$15 |
| % Margin | 2,639% | – | – | – |